CRISPR’s use has vast potential in basic research to add to the understanding of cellular activity and in healthcare for precision therapies for today’s untreatable diseases. To date, some 30 clinical ...
Editas Medicine may have been first to enter the clinic with a gene-editing therapy, but it was beaten to the finish line by Intellia with first-in-human results in June. But it’s not a competition.
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo ...
WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...
1Spatial has launched 1Edit, a touchscreen compatible solution that offers fast and intuitive data-editing in the field or office, 1Spatial said. Trialed by Ordnance Survey Ireland (OSi), 1Edit ...
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing Phase 2 trial for NTLA-2002, a CRISPR-based gene editing therapy for an ...
RNA editing is an integral step in generating the diversity and plasticity of cellular RNA signatures. Most editing events convert A to I(G) (adenosine to inosine, which is translated as guanosine), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback